QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

QDEL

22.05

-2.48%↓

NERV

3.79

-3.32%↓

LSTA.US

1.99

-5.24%↓

Search

Fagron

Atidarymo kaina

SektoriusSveikatos priežiūra

20.45 -2.15

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

20.45

Max

20.9

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.4M

46M

Pardavimai

34M

476M

P/E

Sektoriaus vid.

17.564

105.69

Dividendų pajamingumas

1.7

Pelno marža

9.569

Darbuotojai

3,989

EBITDA

16M

87M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.70%

2.37%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

66M

1.5B

Ankstesnė atidarymo kaina

22.6

Ankstesnė uždarymo kaina

20.45

Naujienos nuotaikos

By Acuity

50%

50%

171 / 374 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-13 21:34; UTC

Uždarbis

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

2025-11-13 23:45; UTC

Rinkos pokalbiai

Nikkei May Fall After Wall Street's Weakness -- Market Talk

2025-11-13 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

2025-11-13 23:41; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Dip-Buying -- Market Talk

2025-11-13 23:24; UTC

Uždarbis

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

2025-11-13 23:24; UTC

Uždarbis

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

2025-11-13 23:23; UTC

Uždarbis

JBS NV 3Q EPS 52c >JBS

2025-11-13 23:23; UTC

Uždarbis

JBS NV 3Q Sales $22.6B >JBS

2025-11-13 23:04; UTC

Rinkos pokalbiai

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

2025-11-13 22:02; UTC

Uždarbis

Nu Holdings 3Q Net $783M >NU

2025-11-13 22:01; UTC

Uždarbis

Nu Holdings 3Q Rev $4.2B >NU

2025-11-13 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

2025-11-13 21:50; UTC

Uždarbis

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

2025-11-13 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

2025-11-13 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

2025-11-13 21:36; UTC

Įsigijimai, susijungimai, perėmimai

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

2025-11-13 21:33; UTC

Rinkos pokalbiai

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

2025-11-13 21:33; UTC

Uždarbis

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

2025-11-13 21:31; UTC

Uždarbis

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

2025-11-13 21:25; UTC

Uždarbis

Figure Tech Solutions 3Q Rev $156.4M >FIGR

2025-11-13 21:25; UTC

Uždarbis

Figure Tech Solutions 3Q EPS 34c >FIGR

2025-11-13 21:23; UTC

Uždarbis

Intchains Group 3Q Rev $1.3M >ICG

2025-11-13 21:03; UTC

Uždarbis

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

2025-11-13 21:02; UTC

Uždarbis

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

2025-11-13 21:01; UTC

Uždarbis

Applied Materials 4Q Rev $6.8B >AMAT

2025-11-13 21:01; UTC

Uždarbis

Applied Materials 4Q Gross Margin 48.0% >AMAT

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

171 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat